Comment on Scientists regenerate neurons that restore walking in mice after paralysis from spinal cord injury
cooopsspace@infosec.pub 1 year ago
Insurance: Nah we aren’t gonna cover it. And for some reason our economical opinion trumps your own doctors medical opinion.
“Yeahhhhhh here’s the thing, a wheelchair costs fifty dollars, while the revolutionary treatment that will give you full use back is fifty ONE dollars…
So you see, there really is only one sensible option…” -every insurance company everywhere even if the prices were literal
But but… If I can get back to work I can make the $1 whilst also getting back into the workforce and by extention the tax base providing a lifetime of benefit to the public.
Denied.
ikapoz@sh.itjust.works 1 year ago
This is actually one case insurance companies would be ALL OVER a real fix. People with spinal injuries have tons of medical complications that cost throughout their entire life. An insurance company would definitely be interested in unloading persistent fiscal drains like that.
Don’t get me wrong, the medical insurance industry is a fucking terror, especially in the US with the degree of regulatory capture involved. In this one case though, a real cure would serve their interests at anything less than a massive cost on their part.
Jax@sh.itjust.works 1 year ago
If that’s the case, wouldn’t the same logic be applied to novel cancer treatments? Last time I checked those have a tendency to evaporate mysteriously, and insurance companies weren’t exactly stopping it.
Idk, just seams a little idealistic.
ikapoz@sh.itjust.works 1 year ago
The only ideal that type of company has at its heart is the pursuit of profit. If they see a real cure that costs less than the long term “maintenance” care they would be all over it. If not, then not.
Novel cancer treatments aren’t a terribly good comparison in my opinion. Rarely does a single one in isolation offer a clear and permanent cure - though with any categorization that broad there are of course exceptions.
Hell, when scientists identify care that is likely enough to prevent the need of reactive treatment insurance companies often make it free to lower their overall costs - teeth cleaning and flu shots for example. That’s not altruism on their part, it’s economics.
Ryantific_theory@lemmy.world 1 year ago
The difference though is that this treatment would require hundreds of hours of ongoing work from medical professionals for each treatment. What they did was use single cell RNA sequencing to determine which subpopulations of cells are supposed to connect and where, before stimulating cell growth and guiding each RNA mapped subpopulation to where it’s roughly supposed to go. That’s one thing for anatomically complete sub-millimeter spinal cord injuries in mice, but a massive endeavor for human spinal cords.
If you’ve seen the bioengineered cancer treatments where researchers grow immune cells to target a single individual’s tumor, the amount of specialized work that goes into that pales to what current technology would require for this sort of spinal regeneration, and that’s for relatively simple small scale lesions. Multiple lesions or large scale cell death could result in attempting to selectively guide millions of microscopic axons in neat clusters for over a foot.
I wouldn’t be surprised if insurance companies refused to pay for cell regrowth, and instead went for implants that are comparatively much simpler to install and modify in brain-computer interfaces that skip over the damage. This is a great advancement and does open the door for recovering from spinal cord damage, but this is one of those treatments that people are going to get because they need to fill FDA trials and won’t charge, or because the patient is filthy rich.
bob_wiley@lemmy.world 1 year ago
Ryantific_theory@lemmy.world 1 year ago
While that’s true, this isn’t a specific engineering problem. You need to grab a single cell from each relevant subcluster of neurons in the spinal cord, spatially record the exact positioning, send it off to have RNA seq. done, sample all of the subclusters of the target area, spatially record exact positioning, send it off to have RNA seq done, resample based off of RNA seq data, begin axon regrowth of a single subcluster, and then repeat after every growth cycle to ensure the targeting is holding.
You can improve RNA sequencing machines to reduce runtime, improve spatial tracking to make it easier to keep track of the anatomy, but without sci-fi advances in implant technology you can’t get around the sheer amount of procedural time requiring MD-PhDs and post docs to be involved in every visit.
One of the issues with medical technology is that we know far more about how the human body operates than we can control, so compared to biological structures our manipulation of biology at the cell specific level is relatively crude. I’m not saying tech won’t catch up, but it’s going to be ruinously involved for a very long time.